Sucampo Pharmaceuticals Inc.

Bethesda, Md. • 301-961-3400 •

Exchange and Ticker: Nasdaq: SCMP

Filing Range: 3.12M shares @ $14.00 to $16.00

Offering Price: $11.50

Close on First Day: $11.99

Offering Size: $43.10M

Shares Outstanding: 41,729,568

Underwriter: Cowen

Co-managers: CIBC World Markets Inc./ Leerink Swann & Co.

Company Counsel: Wilmer Cutler Pickering Hale & Dorr LLP

Manager Counsel: Cleary Gottlieb Steen & Hamilton

Auditor: Pricewaterhouse Coopers LLP

Market Capitalization on 8/31/07: $531.63M

Close price at current month end: $12.74


Pharmaceutical company focused on the discovery, development and commercialization of drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. The therapeutic potential of prostones was first identified by one of the founders, Dr. Ryuji Ueno. The company is developing prostones with novel mechanisms of action for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders for which there are unmet or underserved medical needs and significant commercial potential. Competitors include Novartis Pharmaceuticals, Braintree Laboratories, Dynogen Pharmaceuticals, Wyeth Pharmaceuticals, Theravance and Microbia.


Diamond Capital, Fujisawa Research Institute of America, Intel Capital, Mizuho Capital Co., Tokio Marine & Fire Insurance Co., UFJ Capital Co.

Source: Thomson Financial